A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
Amelia-1
Phase 1/2 Recruiting
52 enrolled
P300
Phase 1/2 Recruiting
252 enrolled
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Phase 1/2 Recruiting
134 enrolled
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Phase 1/2 Recruiting
183 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
Phase 1/2 Recruiting
310 enrolled
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
Phase 1/2 Recruiting
255 enrolled
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Phase 1/2 Recruiting
54 enrolled
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
263 enrolled 2 FDA
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
225 enrolled
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/2 Recruiting
554 enrolled
PRIMAVERA
Phase 1/2 Recruiting
161 enrolled
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Phase 1/2 Recruiting
100 enrolled
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Phase 1/2 Recruiting
107 enrolled
MoonROSE
Phase 1/2 Recruiting
285 enrolled
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Phase 1/2 Recruiting
100 enrolled
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Phase 1/2 Recruiting
25 enrolled
LINKER-MM1
Phase 1/2 Recruiting
387 enrolled 2 FDA
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1/2 Recruiting
324 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
540 enrolled
MK-6070-002
Phase 1/2 Recruiting
262 enrolled
IDeate-Prostate02
Phase 1/2 Recruiting
360 enrolled
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Phase 1/2 Recruiting
138 enrolled
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Phase 1/2 Recruiting
162 enrolled
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Phase 1/2 Recruiting
224 enrolled
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Phase 1/2 Recruiting
132 enrolled
PARTHENON
Phase 1/2 Recruiting
180 enrolled
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
160 enrolled
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2 Recruiting
146 enrolled
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
200 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
MK-5684-01A
Phase 1/2 Recruiting
220 enrolled
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase 1/2 Recruiting
280 enrolled
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Phase 1/2 Recruiting
380 enrolled
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
370 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Phase 1/2 Recruiting
482 enrolled
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Phase 1/2 Recruiting
245 enrolled
MK-3120-003
Phase 1/2 Recruiting
45 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
MK-3475-06F
Phase 1/2 Recruiting
60 enrolled
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Phase 1/2 Recruiting
165 enrolled
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
TUPELO
Phase 1/2 Recruiting
67 enrolled
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Phase 1/2 Recruiting
94 enrolled
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Phase 1/2 Recruiting
29 enrolled